Intra-Cellular Therapies
Our Mission. Our mission is to deliver innovative treatments to improve the lives of individuals with neuropsychiatric, neurologic, and other disorders to reduce the burden on patients and their caregivers.
Pipeline | Intracellular Therapies
Intra-Cellular Therapies’ pipeline is focused on the following platforms: lumateperone, ITI-1284-ODT-SL, phosphodiesterase 1 (PDE1) inhibitors, ITI-333 and ITI-1500 series. ITI-1284 is a deuterated form of lumateperone, a new chemical entity formulated as an oral disintegrating tablet for sublingual administration.
Johnson & Johnson Strengthens Neuroscience Leadership with …
6 days ago · Intra-Cellular Therapies is a biopharmaceutical company founded on Nobel Prize-winning research that allows us to understand how therapies affect the inner workings of cells in the body. The company leverages this intracellular approach to develop innovative treatments for people living with complex psychiatric and neurologic diseases.
J&J buys Intra-Cellular in $14.6 billion deal, delving further into ...
5 days ago · Johnson & Johnson will spend more than $14 billion to delve further into the treatment of central nervous system disorders by purchasing Intra-Cellular Therapies. The health care giant said Monday that it will pay $132 in cash for each share of Intra-Cellular. That represents a 39% premium to Intra-Cellular’s closing price of $94.87 on Friday.
J&J doubles down on neurological drugs with $14.6 billion Intra ...
6 days ago · Johnson & Johnson said on Monday it would buy neurological drug maker Intra-Cellular Therapies for $14.6 billion, its biggest deal in more than two years, boosting its presence in the market for ...
J&J to Acquire Intra-Cellular for About $14.6 Billion - Bloomberg.com
6 days ago · Johnson & Johnson agreed to acquire Intra-Cellular Therapies Inc., a company focused on treatments for central nervous system disorders, for about $14.6 billion.
Intra-Cellular Therapies, Inc. (ITCI) - Yahoo Finance
Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily...
Intra-Cellular Therapies Announces Positive Phase 3 Topline …
Apr 16, 2024 · Intra-Cellular Therapies is a biopharmaceutical company founded on Nobel prize-winning research that allows us to understand how therapies affect the inner-workings of cells in the body. The company leverages this intracellular approach to develop innovative treatments for people living with complex psychiatric and neurologic diseases.
Intra-Cellular Therapies Announces Positive Topline Results in …
Jun 18, 2024 · Intra-Cellular Therapies is a biopharmaceutical company founded on Nobel prize-winning research that allows us to understand how therapies affect the inner-workings of cells in the body. The company leverages this intracellular approach to develop innovative treatments for people living with complex psychiatric and neurologic diseases.
Update: Johnson & Johnson acquires Intra-Cellular Therapies
5 days ago · Johnson & Johnson (J&J) has announced it will acquire Intra-Cellular Therapies, a company specialising in central nervous system disorder treatments. The news was first reported by Bloomberg late on Sunday (12 January) and confirmed by Johnson and Johnson through an official announcement on 13 January.
- Some results have been removed